Citation: Li YJ, Minear MA, Qin X, et al; for the FECD Genetics Consortium. Mitochondrial polymorphism A10398G and Haplogroup I are associated with Fuchs' endothelial corneal dystrophy. Invest Ophthalmol Vis Sci. 2014;55:4577-4584. DOI:10.1167/ iovs.13-13517 PURPOSE. We investigated whether mitochondrial DNA (mtDNA) variants affect the susceptibility of Fuchs endothelial corneal dystrophy (FECD).
F uchs endothelial corneal dystrophy (FECD), first described by Fuchs in 1910,
1 is characterized by progressive and nonregenerative loss of corneal endothelium. As endothelial cells significantly diminish as the disease advances, patients develop corneal edema with a loss of corneal clarity and progressively lose visual acuity. [1] [2] [3] [4] This disorder affects as many as 4% of the United States population over the age of 40 years, 5, 6 and it occurs predominantly in women, who comprise approximately 75% of cases. 7, 8 While the pathogenesis of FECD remains poorly understood, genetic and environmental factors are thought to contribute to its causation and severity. 6, [9] [10] [11] [12] Genetic predisposition is considered the best predictor for FECD given that many FECD cases show familial clustering. 8, 13 To date, genetic studies of FECD have reported mutations in COL8A2 (multiple interval mapping [MIM] , 120252; chr1p34.3), SLC4A11 (MIM, 610206; chr20p13), ZEB1 (also known as TCF8; MIM, 609141; chr10p11.22), LOXHD1 (MIM, 613072; chr18q21.1), and AGBL1 (MIM, 615496; chr15q25.3), [14] [15] [16] [17] [18] [19] [20] [21] as well as the association of a single nucleotide polymorphism (SNP) rs613872 in transcription factor 4 (TCF4; MIM, 602272; chr18q21.2) with FECD. 22 In particular, the association between rs613872 and FECD has been replicated by multiple studies. [23] [24] [25] [26] [27] In contrast to the significant evidence implicating a genetic component to FECD, knowledge of environmental risk factors for the disease is limited. In the Reykjavík eye study, Zoega et al. 28 evaluated environmental risk factors associated with the formation of cornea guttae, the key diagnostic criterion for FECD, and reported that smoking more than 20 pack-years increased the risk of corneal guttae formation, whereas higher weight and body mass index decreased the risk of corneal guttae. Recently, Zhang et al. 12 reported that smoking history increases the risk for advanced FECD (grades [4] [5] [6] . Together, these studies suggest that cigarette smoking may be a potential environmental risk factor for FECD.
Aside from nuclear DNA, few studies have examined the role of mitochondrial DNA (mtDNA) in the pathogenesis of FECD. 11, [29] [30] [31] In a serial analysis of gene expression (SAGE) study of donor corneal endothelial cells, 29, 30 several mtDNA genes were found to be the most abundantly expressed genes among all expressed genes identified (table 3 in the study of Gottsch et al. 30 ). Another SAGE comparison between healthy donor corneas and FECD-affected corneas concluded there were more downregulated genes than upregulated genes in FECD corneas. Particularly, mitochondrial transcripts account for the majority of the downregulated genes, including cytochrome b, and NADH dyhydrogenase subunits 1, 2, and 4 ( Table 3 in the study of Gottsch et al. 29 ). A case study of an FECD patient with other health complications, such as sensorineural hearing loss, diabetes, cardiac conduction defects, ataxia, and hyperreflexia, identified missense substitutions in lymphocyte mtDNA at mt15257 (G to A, in the cytochrome b subunit of complex III) and mt4216 (T to C, in the ND1 subunit of complex I). 32 Jurkunas et al. 11 reported a set of significantly down-regulated antioxidant genes, including superoxide dismutase 2 (SOD2) in mitochondria, expressed in the corneal endothelium of FECD. Therefore, they proposed that the mitochondrial genome may be a specific target for oxidative stress in FECD, and that it may be involved in the pathogenesis of FECD.
Human mtDNA, a circular molecule, encodes 37 mitochondrial genes, which include 22 transfer RNAs (tRNAs), 2 ribosomal RNAs, and 13 protein-coding genes for respiratory chain subunits that are essential for cellular energy production. 33 As a byproduct of energy production, mitochondria also generate most of the endogenous reactive oxygen species (ROS) of the cell. 33 Therefore, mtDNA is particularly susceptible to oxidative damage and has a higher mutation rate than nuclear DNA due to its proximity to high ROS production and its limited DNA-repair capacity. 34 Additionally, corneal endothelial cells contain a large number of mitochondria 35 to G1719A  G4580A  T7028C  G8251A  G9055A A10398G  A12308G  G13368A A13708G  G16391A  SNP rsID  rs3928305 rs28357975 rs2015062 rs3021089 -rs2853826  rs2853498  rs3899498 rs28359178 rs34301918  Gene locus  16S rRNA ND2  COI  COII  ATPase6 ND3  tRNA Leu  ND5  ND5  D-loop  Corresponding SNP in array* -
* SNPs available in the Illumina HumanOmini 2.5-4 array bead chip. The map position is off for one to two base pairs from the conventional designation because the Homo_sapiens_MT assembly was used in array bead chip instead of GRCh37.p10, which was used for the conventional mitochondrial haplogroup markers (refer to the NCBI dbSNP database). rsID, reference sequence ID in dbSNP; -, not applicable. Haplogroup SNP definitions taken from the study of Torroni et al. 37 generate the energy required for the active transport of water and ions from the stroma to maintain the corneal deturgescence required for visual acuity. 36 Therefore, it is plausible that these cells generate high levels of ROS, leading to increased oxidative stress.
Since mtDNA is transmitted maternally without undergoing recombination, it has been used widely in evolutionary studies. As a result, mtDNA haplogroups have been well established for different ethnic groups, and this has led to our understanding of human evolutionary patterns across different continents. These mtDNA haplogroups also can serve as good surrogates for investigating the role of the mitochondrial genome in influencing disease risk. The nine most common European mtDNA haplogroups are defined by 10 SNPs, 37 and some have been reported to be associated with several human diseases, including Alzheimer disease, 38 Parkinson disease, 39, 40 and various ocular diseases, such as age-related macular degeneration (AMD), 41 primary open angle glaucoma (POAG), 42 and keratoconus. 43 We, therefore, hypothesized that mtDNA variants and haplogroups might contribute to FECD genetic susceptibility. We investigated the role of European mtDNA haplogroups in FECD risk using patients of European ancestry, and also examined whether their effect of mtDNA on FECD risk changes in the presence of the rs613872 risk allele or cigarette smoking, two known risk factors for FECD.
MATERIALS AND METHODS

Ethics Statement
Our study was performed in accordance with the Declaration of Helsinki, and the guideline of the institutional review boards (IRB) at the Duke University Medical Center and at Case Western Reserve University (CWRU). The Fuchs research groups at sites obtained the appropriate IRB approval for research on human subjects before initiating recruitment of study participants, and all individuals provided written, informed consent. The discovery dataset included control participants from the Duke University POAG Genetics group, 44 which also were recruited under the approval of the Duke IRB and consented to allow their biological samples to be used by other research studies.
Study Participants
All FECD cases underwent detailed ophthalmic examination, including slit-lamp biomicroscopy, to determine FECD severity as described previously. 23 Grading of disease severity was determined using a slightly modified version of the Krachmer scale classification system. 13 We defined cases based on equivalent grading between Duke and CWRU; that is, grade ‡ 2 for Duke subjects is equivalent to grade ‡ 3 for CWRU subjects. Controls were required to have a normal cornea during slit-lamp examination and to be 45 years of age or older.
This study included a discovery dataset from the Duke FECD genetic study (described previously 23 ) and a replication dataset extracted from the FECD Genetics Consortium's ongoing genome wide association study (GWAS, see Table 1 for sample sizes). A description of the GWAS design can be found on the National Institutes of Health (NIH) dbGaP website (available in the public domain at http://www.ncbi. nlm.nih.gov/gap; study accession, phs000421.v1.p1). Only individuals of European ancestry were included. The discovery dataset consists of 530 unrelated FECD cases and 498 unrelated controls. All 530 cases and 161 of the control subjects were recruited by the FECD clinical team at the cornea clinic in the Duke University Eye Center; the other 337 control samples were subjects without glaucoma from the Duke POAG genetic study. All POAG control subjects had detailed eye examinations and showed no corneal abnormalities at the time of POAG study enrollment.
The FECD GWAS consisted of 3996 unrelated individuals, which included 677 individuals (518 cases and 159 controls) from the Duke FECD genetic study, 1440 individuals (885 cases and 554 controls) recruited from CWRU, and 1879 controls from the genetic variation of refractive error substudy of the Age-Related Eye Disease Study (AREDS) from dbGaP (available in the public domain at http://www.ncbi.nlm.nih.gov/gap; phs000429.v1.p1). The AREDS samples selected for use in the FECD GWAS had no prior cataract surgery or corneal dystrophies. To form two replication datasets, we used FECD cases from CWRU and controls from either all GWAS controls (GWAS1 subset, 857 cases and 2343 controls) or all non-Duke GWAS controls (GWAS2 subset, 857 cases and 2186 controls). All samples selected for replication datasets also were of European ancestry, and all controls were 45 years of age or older.
We created additional subsets by stratifying the Duke discovery dataset using grade level, TCF4 SNP rs613872 genotype, and cigarette smoking status. The Grade 3þ subset contained 457 FECD cases with grade ‡ 3 and all 498 controls. The TCF4 subset contained 529 FECD cases and 494 controls that had rs613872 genotype data available. For cigarette smoking, we investigated two binary cigarette smoking statuses: current smoker, whether a participant was currently smoking cigarettes at the time of study enrollment; and ever smoker, whether a participant had ever smoked cigarettes (either currently or in the past as a former smoker). The current smoker subset contained 234 FECD cases and 119 controls, whereas the ever smoker subset contained 435 FECD cases and 428 controls (Table 1) . There were more controls in the ever smoker subset because POAG controls have ever smoking status data available, but lack current versus former smoking status data.
Mitochondrial Haplogroups and Genotyping
European mtDNA haplogroups can be differentiated by 10 SNPs. 37 Table 2 summarizes the conventional mtDNA marker names, the current dbSNP rsIDs if available, the corresponding marker names from the GWAS genotyping array if available, and how the nine common European mtDNA haplogroups are defined by the alleles of the 10 mtDNA SNPs. For the discovery dataset, all 10 SNPs were genotyped with custom-designed TaqMan allelic discrimination assays (Life Technologies, formerly Applied Biosystems, Inc., Foster City, CA, USA), which use unlabeled PCR primers and two allele-specific probes containing the TaqMan minor groove binding group (MGB) probe, and either a FAM and VIC dye label in a 384-well plate format. The PCR reactions were performed with TaqMan Universal PCR Master Mix on the GeneAmp PCR System 9700 (Applied Biosystems, Inc.), and the ABI7900HT Fast PCR System (Applied Biosystems, Inc.) was used for reading allelic discrimination calls. Quality control (QC) samples, including two Centre d'Etude du Polymorphisme Humain (CEPH) pedigree individuals, one no-template sample, and two duplicate samples (one male, one female), were contained within each quadrant of each 384-well plate.
The FECD GWAS samples were genotyped using the Illumina HumanOmni2.5-4v1_H array. Genotyping was performed by the Center for Inherited Disease Research (CIDR) at Johns Hopkins University (Baltimore, MD, USA), and rigorous QC checks were conducted by the Genetics Coordinating Center at the University of Washington (Seattle, WA, USA). Only three of the 10 European haplogroup markers are present on this chip: A10398G (MitoG10399A), A12308G (MitoA10309G), and G16391A (MitoG16393A). The minor base pair position differences are due to different genetic map assemblies for mtDNA markers used in the haplogroup literature 45 and the Illumina SNP array (refer to NCBI dbSNP, Table 2 ).
Statistical Analysis
The number and percentage of females, and the average (SD) age at enrollment were computed for the discovery and replication datasets. Since mtDNA is a haploid genome, each marker was coded as a binary variable based on the nucleotide that an individual carries: 1 for the minor allele, 0 for the common allele. Minor allele frequency (MAF), therefore, is equivalent to the proportion of samples carrying the minor allele. Logistic regression was applied to test for association between FECD and either all 10 mtDNA SNP markers in the discovery dataset or three mtDNA SNP markers in the replication dataset; these models included covariate adjustment for age and sex. The odds ratio (OR) and its 95% confidence interval (CI) were obtained for each marker along with a P value.
For haplogroup association analyses, each subject was assigned a haplogroup based on the allele combinations listed in Table 2 . Haplogroup frequencies were computed in the discovery dataset for cases and controls. The same logistic regression model with covariate adjustment of age and sex was applied to test association between each haplogroup and FECD. Since haplogroup is specified as a categorical variable with more than two levels, we tested each haplogroup against a common reference haplogroup, Haplogroup H, which is the most common European haplogroup 45 (40.4% in our dataset). This approach allowed us to evaluate the effects of all haplogroups consistently. The haplogroup analyses were performed across the entire discovery dataset and across all four subsets (Grade 3þ
All statistical analyses performed for the discovery dataset were performed using SAS software, release 9.3 (SAS, Inc., Cary, NC, USA). The analyses for GWAS1 and GWAS2 were performed using PLINK 46 (available in the public domain at http://pngu.mgh.harvard.edu/~purcell/plink/).
RESULTS
The sample sizes of the discovery and replication datasets are listed in Table 1 along with demographic data. A total of 1028 samples was included in the discovery dataset with comparable sample sizes between cases and controls (530 vs. 498). Among cases, 457/530 met the grade ‡ 3 criteria (Grade 3þ subset). As expected, there were more females than males, particularly among FECD cases (71.5% females). The average age was 69.5 (SD ¼ 11.0) years old for cases and 65.3 (SD ¼ 10.0) years old for controls. The TCF4 subset is nearly the same size as the full dataset, except five subjects from the full dataset have missing TCF4 rs61872 genotype data. The data available in the current smoker subset are much smaller than that for ever smoker subset due to the inclusion definition of these two categories, and the POAG controls having only ever smoking status data available.
Since samples from the Duke cohort also were included in the FECD GWAS, the minor difference between two replication datasets (GWAS1 and GWAS2) is the inclusion or exclusion of Duke control subjects (N ¼ 157). Therefore, GWAS2 is a completely independent dataset from the discovery dataset, because Duke controls were excluded, while GWAS1 has a larger sample size to increase the statistical power, but including a small number of shared Duke controls. Similar to the discovery dataset, the replication dataset also had more females than males among FECD cases (65.93% females). The average ages also are comparable between cases and controls in the replication dataset (70.6 vs. 69.3 years in GWAS1, Table 1 ).
Haplogroup frequencies are summarized in Table 3 for cases and controls from the discovery dataset. The frequencies of haplogroups in our controls (Table 3) did not differ appreciably from those in a previous report of the North American control population. 45 As expected, Haplogroup H is the most common haplogroup in our dataset (40.4%), followed by Haplogroups U (14.8%) and T (11.8%, Table 3 ). As for the marker-specific MAFs derived from all subjects, G4580A and G16391A are the rarest alleles with MAF ¼ 3%, followed by G8251A with MAF ¼ 7% (Table 4) . Nominal significant is indicated in bold. Table 4 summarizes the association results of mtDNA markers and haplogroups in the discovery dataset. Among mtDNA variants, only A10398G showed significant association with FECD (P ¼ 0.034). The 10398G allele was associated with a decreased risk (protective effect) of FECD (OR ¼ 0.72; 95% CI ¼ 0.53, 0.98). The A10398G marker remains significantly associated with higher graded FECD in the Grade 3þ subset (P ¼ 0.020). Of the three markers that were present in our GWAS data within the replication dataset, we identified significant association between 10398G and FECD in GWAS1 (OR ¼ 0.79; CI ¼ 0.65, 0.96; P ¼ 0.019) and GWAS2 (OR ¼ 0.81; CI ¼ 0.66, 0.98; P ¼ 0.035; Table 5 ). The other two markers (A12308G and G16391A) did not show evidence of significant association with FECD in the GWAS replication subsets.
Mitochondrial Variants and Haplogroups for FECD
Of the nine common European haplogroups, only Haplogroup I was significantly associated with FECD in the entire discovery dataset (P ¼ 0.041) and in the Grade 3þ subset (P ¼ 0.029; Tables 4, 5 When we control for the effect of rs613872 (the TCF4 subset), we did not detect significant association in the TCF4 subset at the single marker level, but as expected TCF4 rs613872 is associated strongly with FECD (P < 0.000001 Table 5 ).
We observed a consistent protective effect for the 10398G allele after controlling for current smoker status (OR ¼ 0.51, P ¼ 0.012) and ever smoker status (OR ¼ 0.68, P ¼ 0.024, Table  5 ). Similarly, Haplogroup I still shows a protective effect for FECD after controlling for current smoker status (OR ¼ 0.15, P ¼ 0.008) and ever smoker status (OR ¼ 0.34, P ¼ 0.013). Although smoking status itself was not a significant covariate in subset analyses, the effects of A10398G and Haplogroup I on FECD appeared to be slightly stronger than those derived from the models that did not control for the effect of smoking. Additionally, T7028C was significantly associated with FECD after adjusting for current smoker status (P ¼ 0.007), as was G16391A after adjusting for either smoking status (P ¼ 0.034 for current smoker and P ¼ 0.029 for ever smoker). Finally, Haplogroup K showed the same protective effect as Haplogroup I with OR ¼ 0.31 (95% CI ¼ 0.13, 0.72; P ¼ 0.007) in the current smoker subset and OR ¼ 0.56 (95% CI ¼ 0.32, 0.96; P ¼ 0.04) in the ever smoker subset ( Table 5 ). The comparison of OR and 95% CI among all haplogroups for all subsets from the discovery cohort is depicted in the Figure. 
DISCUSSION
Although evidence suggests a potential role for the mitochondrial genome in FECD, 11, 29, 31, 32 less is known about the effect of variants in the mitochondrial genome on genetic susceptibility for this age-related corneal disorder. To our knowledge, this is the first study to investigate the association between mtDNA markers or European mtDNA haplogroups and FECD using large discovery (N ¼ 1028) and replication (max N ¼ 3200) datasets of ethnically matched FECD case and control samples. Based on evidence derived from discovery and replication datasets (GWAS1 and GWAS2), we concluded that A10398G is associated with FECD and its minor 10398G allele decreases the risk of FECD. This significant protective effect was verified further in the higher graded FECD subset (grade ‡ 3) and in two subsets examining either current or ever smoking status. With respect to mitochondrial haplogroups, our analyses using different subsets and models consistently identify Haplogroup I as being associated with a decreased risk of FECD, an effect that is strengthened when we controlled for the effect of cigarette smoking (see Figure) .
The 10 SNPs that define European haplogroups include seven coding markers ( Table 2 ). The A10398G marker is of particular interest, as it is a common nonsynonymous SNP (MAF ¼ 22%) that changes the penultimate amino acid from threonine (Thr) to alanine (Ala) in the mitochondrially-encoded NADH dehydrogenase 3 (MT-ND3) gene. The MT-ND3 gene is one of seven mtDNA encoded subunits contributing to approximately 41 polypeptides of the respiratory Complex I, 33 the first step in the electron transport chain of mitochondrial oxidative phosphorylation that generates usable energy for the cell. The MT-ND3 subunit is located in the hydrophobic protein fragment of Complex I (MIM *516000), which serves as the electron donor to ubiquinone. The A10398G variant probably is one of the most studied mitochondrial polymorphisms. 39, [47] [48] [49] Prior studies have suggested that the G allele of A10398G has a lower potential to generate ROS. 39 Given that excessive ROS production can induce oxidative stress, 50, 51 and that increased oxidative stress can affect FECD risk, 11, 52 our finding of 10398G allele associated with a decreased risk of FECD makes functional sense. We hypothesized that the 10398G allele functions to protect mitochondria from oxidative stress, thereby decreasing the risk of developing FECD. Further studies in the mitochondria of corneal endothelial cells from FECD patients carrying the 10398G allele are needed to confirm this hypothesis.
Haplogroup I is determined by the minor alleles of five mtDNA markers (1719A, 7028T, 8251A, 10398G, 16391A; Table 2 ). The most frequent minor alleles are 7028T (40%) and 10398G (22%). Since C7028T is a synonymous variant, the protective effect observed in Haplogroup I is likely driven by the functional A10398G variant. Furthermore, it is not surprising to see a stronger effect (higher OR) in our Grade 3þ subset, since the number of FECD cases carrying Haplogroup I will be even smaller as the number of FECD cases is reduced in this analysis.
The TCF4 SNP rs613872 is by far the strongest and most consistently associated FECD genetic risk marker [23] [24] [25] [26] [27] and we have noted previously that this association exists within our datasets. 23, 27 For this reason, we also examined whether TCF4 rs613872 affects the association between haplogroups and FECD. Despite the fact that TCF4 rs613872 is significantly associated with an increased risk of FECD, Haplogroup I remains associated with a decreased risk of FECD after controlling for the effect of rs613872. Therefore, we hypothesized that Haplogroup I acts independently from TCF4 in contributing to the pathogenesis of FECD. Although our TCF4 subset analysis also identified Haplogroup X as a risk factor for FECD (P ¼ 0.028), we have reservations regarding this finding because of the low frequency (2.2%) and large OR confidence interval (95% CI ¼ 1.15, 10.34) for Haplogroup X; therefore, replication in a larger dataset is needed.
Cigarette smoking is a probable environmental risk factor for FECD, as it has been reported to affect the risks of developing corneal guttae 28 and advanced FECD. 12 Interestingly, when we adjusted for the effect of cigarette smoking, either current smoker or ever smoker status, we observed stronger association signals for A10398G and Haplogroup I. In addition, Haplogroup K became significantly associated with FECD with the same direction of effect as Haplogroup I. Among nine haplogroups, Haplogroups I, J, and K are the only haplogroups that contain the 10398G allele (Table 2) ; however, it is known that these three haplogroups belong to different mitochondrial clades, 53 implying that the 10398G allele is an independent mutation in these three branches and is likely the main driver for the protective effect to FECD observed in Haplogroups I and K. Since smoking theoretically could contribute to increased oxidative stress, 54, 55 it is possible that carriers of the 10398G allele, Haplogroup I, and/or Haplogroup K have lower ROS production to prevent cellular oxidative stress than others carrying different haplogroups or mtDNA SNPs, resulting in a lower risk of developing FECD.
Although we replicated statistically significant genetic association of the mitochondrial 10398G allele with FECD, our study contains several limitations. First, the significant P values identified in this study ranged between 0.01 and 0.05 despite reasonably large sample sizes. For single marker tests, ideally we should correct for multiple testing of 10 markers by requiring the significance threshold to be P < 0.005 using the most stringent criteria of Bonferroni correction. While the individual dataset does not meet this criterion, we are confident of the genuine association of A10398G with FECD based on the consistent findings from replication and subsets analyses. Furthermore, if we conduct a meta-analysis using Fisher's method 56 for A10398G, the meta-P values for discovery and replication datasets are 0.0054 if GWAS1 is used and 0.0094 if GWAS2 is used. It is promising that meta-P values are close to the boundary of the Bonferroni significance level. Considering the consistent pattern of nominal significant findings in discovery and replication datasets, it is likely that we will identify nominal significant results in additional independent datasets, and the meta-P will likely reach the Bonferroni significance threshold. As for the haplogroup analyses, haplogroups are equivalent to the alleles of a single multiallelic marker. Therefore, a nominal significance threshold is reasonable.
Second, since only three of 10 mtDNA markers for European haplogroups are present on the GWAS SNP bead array used in the replication dataset, we were unable to evaluate whether the association between Haplogroup I and FIGURE. The OR and 95% CI for each haplogroup from five sets of analyses: (1) Full dataset, (2) Grade 3þ subset, where FECD cases have grade ‡ 3, (3) TCF4 subset, adjusting for the effect of rs613872, (4) current smoker subset, adjusting for current smoking status, and (5) ever smoker subset, adjusting for ever smoked status.
FECD would replicate in a larger dataset. Unfortunately, due to the limitation on accessing majority of samples in GWAS1 particularly all control samples from AREDS, we were unable to genotype the other seven mtDNA markers to make full comparison. Given that A10398G is a main contributor to the Haplogroup I and that its significant association with FECD was replicated in our analyses, we believed that it is likely that we would be able to replicate the Haplogroup I association if the other markers were available. Further, the multiple secondary analyses using the subsets from the discovery dataset have identified the Haplogroup I association consistently, which provide additional supporting evidence for Haplogroup I.
Third, the relationship between mtDNA and cigarette smoking status is important as it may provide an explanation of the underlying mechanism of how oxidative stress contributes to FECD. The reason why we did not detect significant association between smoking status and FECD in our dataset may be due to the low number of individuals for which we have cigarette smoking data (current smoker N ¼ 353, or ever smoker N ¼ 863), particularly among controls. Therefore, we should not exclude the role of cigarette smoking for FECD given that our sample size is smaller than the one used by Zhang et al. 12 Finally, our current data do not have sufficient power to test for gene-gene interactions (e.g., mtDNA and TCF4) or gene-environment interactions (e.g., mtDNA and cigarette smoking).
In summary, our analyses suggested that the 10398G allele and Haplogroup I decrease the risk of developing FECD in patients with European ancestry. These data supported the theory that oxidative stress has a role in the pathogenesis of FECD. While these findings need replication in additional independent datasets, the results of this study suggested that future research in the area of mitochondrial-mediated oxidative stress in FECD may lead to the development of novel nonsurgical therapeutic and/or preventive strategies for FECD. Our study presented an important step toward understanding the effect of mtDNA risk variants on FECD.
